The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of systemic anticancer treatment (SACT) with end-of-life (EOL) healthcare use among older patients with hematologic malignancies.
 
Jenny Xiang
Travel, Accommodations, Expenses - Pfizer
 
Lee Cheng
No Relationships to Disclose
 
Maureen Canavan
No Relationships to Disclose
 
John Lin
No Relationships to Disclose
 
David Hui
Consulting or Advisory Role - Eton Pharmaceuticals
 
Ravin Ratan
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I); Medtronic (I)
Honoraria - Peerview; touchIME
Consulting or Advisory Role - InhibRx; SpringWorks Therapeutics
Research Funding - Ayala Pharmaceuticals (Inst); C4 Therapeutics (Inst); SpringWorks Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - SpringWorks Therapeutics; SpringWorks Therapeutics
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; MorphoSys; Pharmacyclics/Janssen
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Jiangong Niu
No Relationships to Disclose
 
Hui Zhao
No Relationships to Disclose
 
Sharon Giordano
No Relationships to Disclose
 
Kerin Adelson
Employment - Emilio Health/Brightline Health (I)
Leadership - Emilio Health/Brightline Health (I)
Stock and Other Ownership Interests - Carrum Health; Emilio Health/Brightline Health (I); Lyra Health (I)
Consulting or Advisory Role - Abbvie; Gilead Sciences; Quantum Health
Patents, Royalties, Other Intellectual Property - Genentech
Other Relationship - Genentech/Roche